AngioSoma Announces New Ecommerce Platform Featuring Innovative Products

Houston, TX, Sep 24, 2018 – AngioSoma (OTC: SOAN) announced today the launch of their new ecommerce site for its retail brand, SomaCeuticals™.  The site,, features products within the Nutraceutical and Cosmeceutical industries currently with a future roadmap to expand product offerings with key partnerships and their growing Amazon storefront. AngioSoma is optimistic the new site launch paired with a new, innovative marketing plan will provide a solid foundation to continue research and development of new product lines designed to enhance lives.

“The new sub-brand and website exemplifies AngioSoma’s innovative approach to the market and our unique target audience with a feature rich ecommerce site that sets the foundation for our future growth plans,” says Alex Blankenship, president of AngioSoma. “As SomaCuetical’s online strategy evolves and customer base matures, we have high expectations of the cumulative impact this brand will have on our overall market strength.”

AngioSoma takes these new market indicators as a challenge to innovate and expand offerings to capitalize on the popularity of these surging industries in alignment with these mega trends.  The global nutraceuticals market is projected to reach $578.23 billion by 2025, according to a new report by Grand View Research, Inc., and SomaCeuticals™ is well positioned to expand its market share with new product launches coming early in Q4, 2018.

The invention of cosmeceuticals has revolutionized the cosmetic and personal care industry. These beauty products can resolve the cause of imperfections naturally rather than covering them. Due to this ability, the share of cosmeceuticals is increasing in and It is anticipated that the global cosmeceuticals market will reach $72.2 Billion by 2022.



AngioSoma, Inc. (https://, a Nevada corporation based in Houston, Texas, is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our Somaceuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.


Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.


AngioSoma, Inc.

Alex Blankenship